EIGR

Publicly traded companies mentioned herein: Eiger Biopharmaceuticals Inc (EIGR)

Highlights

The presenter is long shares of small cap biotech Eiger Biopharmaceuticals (EIGR) and believes that it’s pipeline and long-term opportunity are underappreciated by the Street. Despite positive data on its development programs (more on this below), the stock hasn’t done much over the past 2-3 years. In the $10-11 range, he sees a very favorable risk/reward setup for bulls, as Lonafarnib could be approved for Hutchinson-Gilford Progeria Syndrome (Progeria, aka Benjamin Button Disease), an extremely rare, autosomal dominant, fatal, premature aging syndrome, by the end of 2020 (“the survival data is fantastic”). EIGR would receive a priority review voucher (PRV) if/when Lonafarnib is approved. The ability to quickly monetize Lonafarnib will reduce cash burn while it pursues the larger opportunity: Lonafarnib+Ritonavir for hepatitis delta virus (HDV), which could be a $1B product “easily” (vs. a $265MM market cap today).